Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.15B | $1.29B | $21.14 |
| 2024 | $2.19B | $833.04M | $13.92 |
| 2023 | $1.23B | $-295.05M | $-5.16 |
| 2022 | $410.75M | $-709.59M | $-13.05 |
| 2021 | $1.08B | $-408.26M | $-7.99 |
Social Signal Score
Earnings
Thu, Mar 4(in 7 months)
Consensus estimate $7.99 per share
Typical surprise +16.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$7.32 vs $6.27beat
- Thu, May 7$12.25 vs $4.75beat
- Thu, Jul 31$2.94 vs $-0.91beat
- Thu, May 8$2.68 vs $2.89miss
- Thu, Oct 31$1.39 vs $0.01beat
- Thu, May 9$-1.04 vs $-0.80miss
Estimates and results for ARGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $30.97
- Implied price
- $1,239
- Return from $851.29
- 7.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $615.94 — -27.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 28 | 34 | 40 | 46 | 52 |
|---|---|---|---|---|---|
| -2.0% | -8.9% | -5.3% | -2.2% | 0.6% | 3.1% |
| 3.0% | -4.3% | -0.5% | 2.8% | 5.7% | 8.3% |
| 8.0% | 0.4% | 4.3% | 7.8% | 10.8% | 13.6% |
| 13.0% | 5.0% | 9.2% | 12.8% | 16.0% | 18.9% |
| 18.0% | 9.7% | 14.0% | 17.8% | 21.1% | 24.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsreuters.com·6h ago·Negative
Argenx says efgartigimod met main goal in myositis trial Belgian-Dutch immunology company argenx ARGX.BR said its drug efgartigimod met the primary endpoint in a late-stage study treating adults with autoimmune myositis, showing significant improvement in disease activity.
View source ↗